The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up.
R. A. Larson
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
D. Kim
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
G. Rosti
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis; Roche
Research Funding - Novartis
L. Stenke
Consultant or Advisory Role - Novartis
R. Pasquini
Consultant or Advisory Role - Novartis
Honoraria - Bristol-Myers Squibb; Novartis
A. Hoenekopp
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
R. E. Blakesley
Employment or Leadership Position - Novartis
N. J. Gallagher
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
A. Hochhaus
Research Funding - Bristol-Myers Squibb; Novartis
T. P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
G. Saglio
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis
H. Kantarjian
Consultant or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer